Holen Sie sich die Stockscreener-App
737.71
2.51%
-19.02
Vorhandelsmarkt:
740.00
2.29
+0.31%
Schlusskurs vom Vortag:
$756.73
Offen:
$756.65
24-Stunden-Volumen:
492.04K
Relative Volume:
0.68
Marktkapitalisierung:
$77.99B
Einnahmen:
$14.34B
Nettoeinkommen (Verlust:
$4.50B
KGV:
17.75
EPS:
41.5626
Netto-Cashflow:
$3.77B
1W Leistung:
+0.66%
1M Leistung:
-5.62%
6M Leistung:
+30.82%
1J Leistung:
+16.02%
1-Tages-Spanne:
$736.64
$759.47
1-Wochen-Bereich:
$727.96
$761.73
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
737.71 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
433.07 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
691.40 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.36 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
283.03 | 31.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Japan’s New Dupixent Approval - simplywall.st
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Woodstock Corp - MarketBeat
Dakota Wealth Management Boosts Regeneron Pharmaceuticals Stake - National Today
Dakota Wealth Management Has $2.41 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron's 2026 Outlook: Pipeline, Weight Loss Drugs, and Post-Eylea StrategyNews and Statistics - IndexBox
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to "Buy" - MarketBeat
AstraZeneca COPD Success Tests Regeneron Dupixent Growth Story - simplywall.st
Discipline and Rules-Based Execution in REGN Response - Stock Traders Daily
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard disaggregates holdings; reports 0 shares of Regeneron (REGN) - Stock Titan
Regeneron (REGN) and Sanofi Announce Dupixent Approval in Japan to Treat Bullous Pemphigoid - insidermonkey.com
Is Regeneron a Multimillionaire-Maker Stock? - The Globe and Mail
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Benzinga
Regeneron stock price forecast: consolidation likely as REGN faces resistance below recent highs - Traders Union
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Global X Japan Co. Ltd. - MarketBeat
Sarcopenia Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Oncocross, Biophytis, MyMD Pharma, Novartis, Regeneron Pharma, Merck Sharp & Dohme - StreetInsider
5 Best Debt Free Stocks to Buy Right Now - Insider Monkey
Regeneron Can't Sink Disability Bias Claims Over Scheduling - Law360
Wealth Enhancement Advisory Services LLC Has $17.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure, Closing at $728.64 - Markets Mojo
Growth Value: Why is Regeneron Pharmaceuticals Inc stock going down2026 Rallies & Entry Point Strategy Guides - baoquankhu1.vn
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 - The Manila Times
Regeneron sets April 29 earnings release, webcast before open - Stock Titan
How Investors Are Reacting To Regeneron (REGN) Securing Japan’s First Targeted Bullous Pemphigoid Therapy Approval - Yahoo Finance
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026? - TradingView
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
Regeneron Pharma stock faces pipeline pressure amid Dupixent sales surge and oncology setbacks - AD HOC NEWS
The Bull Case For Regeneron Pharmaceuticals (REGN) Could Change Following New Japanese Dupixent BP Approval - simplywall.st
E. Ohman J or Asset Management AB Sells 1,480 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - WebWire
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Rep. Julia Letlow Buys Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat
Avanza Fonder AB Purchases 1,590 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Assenagon Asset Management S.A. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) - The Manila Times
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid - The Manila Times
Japan clears first targeted drug for blistering skin disease - Stock Titan
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment | Business Information & News | FE - Westlaw Today
Small Biotech Zips Higher On Its Regeneron-Rivaling Test Results - Investor's Business Daily
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment - Reuters
Nordea Investment Management AB Acquires 74,350 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Tokenized Stock (Ondo) price today, REGNon to USD live price, marketcap and chart - CoinMarketCap
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality - BioSpace
How The Regeneron (REGN) Story Is Shifting As Dupixent And Pipeline Expectations Reset - Yahoo Finance
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Weak Share Momentum And Franchise Outlook - simplywall.st
Why Regeneron Pharmaceuticals (REGN) is one of the top gene therapy stocks to buy according to hedge funds - MSN
Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN) - The Globe and Mail
Union Bancaire Privee UBP SA Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.56%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):